Human papillomavirus and cervical cancer;Humanpathogene papillomviren und zervixkarzinom

Deutsches Arzteblatt

Volumn 104, Issue 41, 2007, Pages

  Löning, Martin ^a   Gissmann, Lutz ^b   Diedrich, Klaus ^a   Friese, Klaus ^c   Kreienberg, Rolf ^d   Hillemanns, Peter ^e  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b Deutsches Krebsforschungszentmm Heidelberg   (Germany)

^c Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe   (Germany)

^d UNIVERSITY HOSPITAL ULM   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Cervical carcinoma; HPV; Vaccination; Vaccine; Virus like particle

Indexed keywords

NUCLEIC ACID; PLACEBO; WART VIRUS VACCINE;

ANUS; CANCER INVASION; CANCER REGISTRY; CANCER RISK; CELL CULTURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG EFFICACY; GENETIC ENGINEERING; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; MALIGNANT TRANSFORMATION; NEOPLASM; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCREENING TEST; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DYSPLASIA; VAGINA; VIRUS LIKE AGENT; VULVA;

EID: 35648965596     PISSN: 00121207     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (10)

1. Griffiths M: Nuns, virgins, and spinsters. Rigoni-Stern and cervical cancer revisited. Br J Obst Gynaecol 1991; 98: 797-802.
2. Gissmann L: Linking Human Papillomaviruses to Cervical Cancer: A Long and Winding Road. In: Campo MS (Hrsg.): Papillomavirus Research: From Natural History To Vaccines and Beyond. Norwick UK: Caister Academic Press 2006; 3-11.
3. Munoz N, Bosch FX: HPV and cervical neoplasia: review of case-control and cohort studies. IARC Sci Publ 1992; 119: 251-61.
4. Koutsky LA, Ault KA, Wheeler CM et al.: Proof of principle study investigators, a controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347: 1645-51.
5. Harper DM, Franco EL, Wheeler C et al.: Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial. Lancet 2004; 364: 1757-65.
6. Villa LL, Costa RL, Petta CA et al.: Prophylactic tetravalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271-8.
7. The FUTURE II Study Group: Tetravalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-27.
8. Ault KA, The Future II Study Group: Effect of prophylactic human papillomavirus L1 virus-like particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomized clinical trials. Lancet 2007; 369: 1861-8.
9. Garland SM, Hernandez-Avila M, Wheeler CM et al.: Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 1928-43.
10. Joura EA, Leodolter S, Hernandez-Avila M et al.: Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomized clinical trials. Lancet 2007; 369: 1693-702.